EQT VII portfolio company Certara closes Initial Public Offering
EQT is pleased to announce that on 10 December 2020, the EQT VII portfolio company Certara, Inc. (“Certara”), a global leader in biosimulation based on 2019 revenue, successfully priced its upsized initial public offering of 29,055,000 shares of its common stock at USD 23 per share. Shares of...
EQT portfolio companies respond to COVID-19
As the COVID-19 pandemic disrupts societies and impacts everyday lives, businesses are finding new and creative ways to adapt to the current situation. In the light of this ‘new normal’, many of EQT’s portfolio companies have quickly pivoted their operations in response to the outbreak in order t...
EQT VII acquires health technology company Certara for USD 850 million
EQT VII acquires Certara, the global leader in model-informed (in silico) drug development and regulatory science, focused on optimizing drug development and improving health outcomes Certara’s solutions help to inform and accelerate drug development and regulatory approval processes, while...
Filters applied: #Certara